MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

592

Employees592

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

592

Employees592

MNKD Key Statistics

Market cap

1.03B

Market cap1.03B

Price-Earnings ratio

-22.58

Price-Earnings ratio-22.58

Dividend yield

—

Dividend yield—

Average volume

3.79M

Average volume3.79M

High today

$3.30

High today$3.30

Low today

$3.09

Low today$3.09

Open price

$3.20

Open price$3.20

Volume

3.09M

Volume3.09M

52 Week high

$6.51

52 Week high$6.51

52 Week low

$2.23

52 Week low$2.23

Stock Snapshot

With a market cap of 1.03B, MannKind(MNKD) trades at $3.23. The stock has a price-to-earnings ratio of -22.58.

As of 2026-10-23, MannKind(MNKD) stock has fluctuated between $3.09 and $3.30. The current price stands at $3.23, placing the stock +4.5% above today's low and -2.0% off the high.

The MannKind(MNKD)'s current trading volume is 3.09M, compared to an average daily volume of 3.79M.

In the last year, MannKind(MNKD) shares hit a 52-week high of $6.51 and a 52-week low of $2.23.

MNKD News

Simply Wall St 39m

Did Clinical Data On Furoscix ReadyFlow Just Shift MannKind Investment Narrative?

MannKind Corporation recently reported new clinical data on Furoscix ReadyFlow, showing IV equivalent pharmacokinetic and pharmacodynamic performance across thi...

Investing.com 3d

MannKind at Chardan’s 10th Annual Healthcare Conference: pipeline broadens - Investing.com

...

TipRanks 4d

MannKind initiated with a Buy at Chardan

Chardan analyst Andreas Argyrides initiated coverage of MannKind (MNKD) with a Buy rating and $10 price target The drug-device company’s revenue mix is shifting...

Analyst ratings

89%

of 9 ratings

Buy

88.9%

Hold

11.1%

Sell

More MNKD News

Simply Wall St 5d

MannKind Could Be 62% Undervalued After New Furoscix Data

Advertisement Why Furoscix ReadyFlow matters for MannKind investors MannKind (MNKD) just pushed fresh Furoscix ReadyFlow data into the spotlight at the Heart...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.